Randomized Controlled Multicenter Trial to Evaluate the Effects of Ethyl-2-cyanoacrylate on Pain Intensity and Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades During Radioimmunotherapy
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
pain intensity 24 hours after application of ECA or the standard treatment quantified by the visual analogue scale (VAS)
pain intensity quantified by the visual analogue scale (VAS)
24 hours after application
No
Karin Potthoff, MD
Principal Investigator
National Center for Tumor Diseases, Heidelberg
Germany: Federal Institute for Drugs and Medical Devices
Uni-HD-2010-33-40-1003
NCT01693159
May 2011
October 2013
Name | Location |
---|